The stock of Regeneron Pharmaceuticals, Inc (REGN) has gone down by -19.13% for the week, with a -19.44% drop in the past month and a -27.78% drop in the past quarter. The volatility ratio for the week is 10.91%, and the volatility levels for the past 30 days are 5.70% for REGN. The simple moving average for the past 20 days is -14.15% for REGN’s stock, with a -37.86% simple moving average for the past 200 days.
Is It Worth Investing in Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Right Now?
The price-to-earnings ratio for Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is above average at 12.42x. The 36-month beta value for REGN is also noteworthy at 0.31. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 6 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for REGN is 104.06M, and at present, short sellers hold a 2.69% of that float. The average trading volume of REGN on June 04, 2025 was 1.26M shares.
REGN) stock’s latest price update
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has experienced a decline in its stock price by -0.60 compared to its previous closing price of 490.81. However, the company has seen a fall of -19.13% in its stock price over the last five trading days. forbes.com reported 2025-06-02 that Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was anticipated to become a blockbuster drug, with peak sales projections from Sanofi estimated between $2 billion and $6 billion.
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with Wells Fargo repeating the rating for REGN by listing it as a “Equal Weight.” The predicted price for REGN in the upcoming period, according to Wells Fargo is $580 based on the research report published on May 30, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see REGN reach a price target of $662. The rating they have provided for REGN stocks is “Sector Perform” according to the report published on May 30th, 2025.
Citigroup gave a rating of “Buy” to REGN, setting the target price at $700 in the report published on May 14th of the current year.
REGN Trading at -16.46% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.72% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $844.61 back on Nov 01 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc, valued at $844,610 using the latest closing price.
MARION E MCCOURT, the Officer of Regeneron Pharmaceuticals, Inc, proposed sale 1,000 shares at $844.61 during a trade that took place back on Nov 01 ’24, which means that MARION E MCCOURT is holding shares at $844,610 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.85 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc stands at 0.32. The total capital return value is set at 0.11. Equity return is now at value 15.96, with 12.51 for asset returns.
Based on Regeneron Pharmaceuticals, Inc (REGN), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.46. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 98.59.
Currently, EBITDA for the company is 5.32 billion with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 3.65. The receivables turnover for the company is 2.53for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.
Conclusion
In summary, Regeneron Pharmaceuticals, Inc (REGN) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
